Arbutus Biopharma Corporation (ABUS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 530.30M |
| Enterprise value | 402.74M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 36.67 |
| Price/book (mrq) | 4.63 |
| Enterprise value/revenue | 31.01 |
| Enterprise value/EBITDA | -5.54 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.09 |
| 52-week change 3 | 3.83% |
| S&P500 52-week change 3 | 24.49% |
| 52-week high 3 | 3.2900 |
| 52-week low 3 | 1.6900 |
| 50-day moving average 3 | 2.7472 |
| 200-day moving average 3 | 2.2843 |
Share statistics
| Avg vol (3-month) 3 | 1.39M |
| Avg vol (10-day) 3 | 693.04k |
| Shares outstanding 5 | 188.72M |
| Implied shares outstanding 6 | 180.18M |
| Float 8 | 133.83M |
| % held by insiders 1 | 22.29% |
| % held by institutions 1 | 41.49% |
| Shares short (15 Apr 2024) 4 | 5.17M |
| Short ratio (15 Apr 2024) 4 | 2.58 |
| Short % of float (15 Apr 2024) 4 | 3.69% |
| Short % of shares outstanding (15 Apr 2024) 4 | 2.87% |
| Shares short (prior month 15 Mar 2024) 4 | 4.13M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:5 |
| Last split date 3 | 04 Nov 2010 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -1,252.15% |
Management effectiveness
| Return on assets (ttm) | -29.31% |
| Return on equity (ttm) | -57.54% |
Income statement
| Revenue (ttm) | 12.99M |
| Revenue per share (ttm) | 0.08 |
| Quarterly revenue growth (yoy) | -77.10% |
| Gross profit (ttm) | N/A |
| EBITDA | -78.65M |
| Net income avi to common (ttm) | -74.39M |
| Diluted EPS (ttm) | -0.4400 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 129.24M |
| Total cash per share (mrq) | 0.69 |
| Total debt (mrq) | 8.08M |
| Total debt/equity (mrq) | 7.05% |
| Current ratio (mrq) | 6.70 |
| Book value per share (mrq) | 0.64 |
Cash flow statement
| Operating cash flow (ttm) | -77.93M |
| Levered free cash flow (ttm) | -46.04M |
© 2024 Yahoo. All rights reserved.